EP1208232A4 - Markers for prostate cancer - Google Patents

Markers for prostate cancer

Info

Publication number
EP1208232A4
EP1208232A4 EP00938256A EP00938256A EP1208232A4 EP 1208232 A4 EP1208232 A4 EP 1208232A4 EP 00938256 A EP00938256 A EP 00938256A EP 00938256 A EP00938256 A EP 00938256A EP 1208232 A4 EP1208232 A4 EP 1208232A4
Authority
EP
European Patent Office
Prior art keywords
markers
prostate cancer
prostate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00938256A
Other languages
German (de)
French (fr)
Other versions
EP1208232A1 (en
Inventor
Carlos Cordon-Cardo
Howard I Scher
Andrew Koff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sloan Kettering Institute for Cancer Research
Original Assignee
Sloan Kettering Institute for Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/329,917 external-priority patent/US6972170B1/en
Application filed by Sloan Kettering Institute for Cancer Research filed Critical Sloan Kettering Institute for Cancer Research
Priority to EP04023000A priority Critical patent/EP1512755A3/en
Publication of EP1208232A1 publication Critical patent/EP1208232A1/en
Publication of EP1208232A4 publication Critical patent/EP1208232A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP00938256A 1999-06-10 2000-06-09 Markers for prostate cancer Withdrawn EP1208232A4 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04023000A EP1512755A3 (en) 1999-06-10 2000-06-09 Markers for prostate cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US329917 1999-06-10
US09/329,917 US6972170B1 (en) 1997-12-01 1999-06-10 Markers for prostate cancer
PCT/US2000/016007 WO2000077258A1 (en) 1999-06-10 2000-06-09 Markers for prostate cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP04023000A Division EP1512755A3 (en) 1999-06-10 2000-06-09 Markers for prostate cancer

Publications (2)

Publication Number Publication Date
EP1208232A1 EP1208232A1 (en) 2002-05-29
EP1208232A4 true EP1208232A4 (en) 2003-01-15

Family

ID=23287568

Family Applications (2)

Application Number Title Priority Date Filing Date
EP00938256A Withdrawn EP1208232A4 (en) 1999-06-10 2000-06-09 Markers for prostate cancer
EP04023000A Withdrawn EP1512755A3 (en) 1999-06-10 2000-06-09 Markers for prostate cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP04023000A Withdrawn EP1512755A3 (en) 1999-06-10 2000-06-09 Markers for prostate cancer

Country Status (3)

Country Link
EP (2) EP1208232A4 (en)
CA (1) CA2375228A1 (en)
WO (1) WO2000077258A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972170B1 (en) 1997-12-01 2005-12-06 Sloan-Kettering Institute For Cancer Research Markers for prostate cancer
AU2002356844C1 (en) 2001-10-23 2010-03-04 Amgen Fremont Inc. PSMA antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
WO2006031210A1 (en) * 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
US7834163B2 (en) 2003-06-26 2010-11-16 Exonhit Therapeutics S.A. Prostate specific genes and the use thereof as targets for prostate cancer therapy
ATE400815T1 (en) 2005-08-01 2008-07-15 Sysmex Corp METHOD FOR ASSESSING THE CONSISTENCY OF MALIGNANT TUMORS
EP2727606A3 (en) 2008-09-08 2015-09-23 Psma Development Company, L.L.C. Compounds for killing psma-expressing, taxane-resistant cancer cells
US9994912B2 (en) 2014-07-03 2018-06-12 Abbott Molecular Inc. Materials and methods for assessing progression of prostate cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022478A1 (en) * 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
WO1998033450A1 (en) * 1997-01-31 1998-08-06 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin e
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
WO1999031140A1 (en) * 1997-12-12 1999-06-24 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688665A (en) * 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
US5994071A (en) * 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994022478A1 (en) * 1993-03-30 1994-10-13 The Trustees Of The University Of Pennsylvania PREVENTION OF TUMORS WITH MONOCLONAL ANTIBODIES AGAINST $i(NEU)
WO1998033450A1 (en) * 1997-01-31 1998-08-06 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin e
WO1999004238A2 (en) * 1997-07-15 1999-01-28 Mitotix, Inc. Reagents and methods for diagnosis and prognosis of proliferative disorders
WO1999031140A1 (en) * 1997-12-12 1999-06-24 Genentech, Inc. TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
AALTOMAA S ET AL: "Prognostic value and expression of p21(waf1/cip1) protein in prostate cancer.", THE PROSTATE. UNITED STATES 1 APR 1999, vol. 39, no. 1, 1 April 1999 (1999-04-01), pages 8 - 15, XP002213568, ISSN: 0270-4137 *
AGUS D B ET AL: "RESPONSE OF PROSTATE CANCER TO ANTI-HER-2/NEU ANTIBODY IN ANDROGEN DEPENDENT AND -INDEPENDENT HUMAN XENOGRAFT MODELS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 1 October 1999 (1999-10-01), pages 4761 - 4764, XP000919490, ISSN: 0008-5472 *
ARAI YOICHI ET AL: "C-erbB-2 Oncoprotein: A potential biomarker of advanced prostate cancer.", PROSTATE, vol. 30, no. 3, 1997, pages 195 - 201, XP002214672, ISSN: 0270-4137 *
BARETTON G B ET AL: "Proliferation- and apoptosis-associated factors in advanced prostatic carcinomas before and after androgen deprivation therapy: prognostic significance of p21/WAF1/CIP1 expression.", BRITISH JOURNAL OF CANCER. SCOTLAND MAY 1999, vol. 80, no. 3-4, May 1999 (1999-05-01), pages 546 - 555, XP002213569, ISSN: 0007-0920 *
BASELGA J ET AL: "RECOMBINANT HUMANIZED ANTI-HER2 ANTIBODY (HERCEPTIN TM) ENHANCES THE ANTITUMOR ACTIVITY OF PACLITAXEL AND DOXORUBICIN AGAINST HER2/NEU OVEREXPRESSING HUMAN BREAST CANCER XENOGRAFTS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 58, no. 13, 1998, pages 2825 - 2831, XP000919190, ISSN: 0008-5472 *
CARIOU S ET AL: "PROGNOSTIC IMPLICATIONS OF EXPRESSION OF THE CELL CYCLE INHIBITOR PROTEIN P27", BREAST CANCER RESEARCH AND TREATMENT, NIJHOFF, BOSTON, US, vol. 1-3, no. 52, 1998, pages 29 - 41, XP001080251, ISSN: 0167-6806 *
CHEN Y ET AL: "Increased cell growth and tumorigenicity in human prostate LNCaP cells by overexpression to cyclin D1.", ONCOGENE. ENGLAND 16 APR 1998, vol. 16, no. 15, 16 April 1998 (1998-04-16), pages 1913 - 1920, XP002213572, ISSN: 0950-9232 *
CHUNG-ANG JOURNAL OF MEDICINE, vol. 24, no. 1, March 1999 (1999-03-01), pages 1 - 11, ISSN: 0253-6250 *
CORDON-CARDO C ET AL: "DISTINCT ALTERED PATTERNS OF P27 GENE EXPRESSION IN BENIGN PROSTATIC HYPERPLASIAAND PROSTATIC CARCINIMA", JOURNAL OF THE NATIONAL CANCER INSTITUTE, US DEPT. OF HEALTH, EDICATIONAND WELFARE, PUBLIC HEALTH, US, vol. 17, no. 90, 2 September 1998 (1998-09-02), pages 1284 - 1291, XP001080206, ISSN: 0027-8874 *
COTE RICHARD J ET AL: "Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma.", JOURNAL OF THE NATIONAL CANCER INSTITUTE (BETHESDA), vol. 90, no. 12, 17 June 1998 (1998-06-17), pages 916 - 920, XP002931303, ISSN: 0027-8874 *
CRAFT NOAH ET AL: "A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase.", NATURE MEDICINE, vol. 5, no. 3, March 1999 (1999-03-01), pages 280 - 285, XP002213575, ISSN: 1078-8956 *
CURNOW R T: "CLINICAL EXPERIENCE WITH CD64-DIRECTED IMMUNOTHERAPY. AN OVERVIEW", CANCER IMMUNOLOGY AND IMMUNOTHERAPY, BERLIN, DE, vol. 45, no. 3/4, November 1997 (1997-11-01), pages 210 - 215, XP000918956, ISSN: 0340-7004 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 1999 (1999-03-01), LEE TAE YOON ET AL: "Immunohistochemical expression of p53 and MDM-2 protein in various epithelial carcinomas.", XP002213577, Database accession no. PREV199900406745 *
FERNÁNDEZ P L ET AL: "Expression of p27/Kip1 is down-regulated in human prostate carcinoma progression.", THE JOURNAL OF PATHOLOGY. ENGLAND APR 1999, vol. 187, no. 5, April 1999 (1999-04-01), pages 563 - 566, XP002199163, ISSN: 0022-3417 *
GUMBINER LAURA M ET AL: "Overexpression of cyclin D1 is rare in human prostate carcinoma.", PROSTATE, vol. 38, no. 1, 1 January 1999 (1999-01-01), pages 40 - 45, XP001105184, ISSN: 0270-4137 *
GUO Y ET AL: "Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES DEC 1997, vol. 3, no. 12 Pt 1, December 1997 (1997-12-01), pages 2269 - 2274, XP002916572, ISSN: 1078-0432 *
HAN EDWARD KYU-HO ET AL: "Cyclin D1 expression in human prostate carcinoma cell lines and primary tumors.", PROSTATE, vol. 35, no. 2, May 1998 (1998-05-01), pages 95 - 101, XP002213571, ISSN: 0270-4137 *
JAMES N ET AL: "PHASE II TRIAL OF THE BISPECIFIC ANTIBODY MDX-H210 (ANTI-HER2/NEU X ANTI-CD64) COMBINED WITH GM-CSF IN PATIENTS WITH ADVANCED PROSTATE AND RENAL CELL CARCINOMAS THAT EXPRESS HER2/NEU", BRITISH JOURNAL OF CANCER, LONDON, GB, vol. 78, no. SUPPL 2, 5 July 1998 (1998-07-05), pages 19, XP000940750, ISSN: 0007-0920 *
KOENEMAN K S ET AL: "OSTEOMIMETIC PROPERTIES OF PROSTATE CANCER CELLS: A HYPOTHESIS SUPPORTING THE PREDILECTION OF PROSTATE CANCER METASTASIS AND GROWTH IN THE BONE ENVIRONMENT", PROSTATE, WILEY-LISS, NEW YORK, NY, US, vol. 39, 1999, pages 246 - 261, XP002946861, ISSN: 0270-4137 *
LEE C T ET AL: "OVEREXPRESSION OF THE CYCLIN-DEPENDENT KINASE INHIBITOR P16 IS ASSOCIATED WITH TUMOR RECURRENCE IN HUMAN PROSTATE CANCER", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 5, no. 5, May 1999 (1999-05-01), pages 977 - 983, XP001016336, ISSN: 1078-0432 *
LLOYD RICARDO V ET AL: "p27Kip1: A multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers.", AMERICAN JOURNAL OF PATHOLOGY, vol. 154, no. 2, February 1999 (1999-02-01), pages 313 - 323, XP002931302, ISSN: 0002-9440 *
MARZO DE ANGELO M ET AL: "Prostate stem cell compartments: Expression of the cell cycle inhibitor p27kip1 in normal, hyperplastic, and neoplastic cells", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 153, no. 3, September 1998 (1998-09-01), pages 911 - 919, XP002199162, ISSN: 0002-9440 *
MCARTHUR J G ET AL: "Cancer gene therapy with novel chimeric p27/p16 tumor suppressor genes.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, vol. 40, March 1999 (1999-03-01), 90th Annual Meeting of the American Association for Cancer Research;Philadelphia, Pennsylvania, USA; April 10-14, 1999, March, 1999, pages 630, XP002144030, ISSN: 0197-016X *
OSMAN I ET AL: "Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES AUG 1999, vol. 5, no. 8, August 1999 (1999-08-01), pages 2082 - 2088, XP002213576, ISSN: 1078-0432 *
ROSS JEFFREY S ET AL: "Contribution of HER-2/neu oncogene expression to tumor grade and DNA content analysis in the prediction of prostatic carcinoma metastasis.", CANCER (PHILADELPHIA), vol. 72, no. 10, 1993, pages 3020 - 3028, XP002214671, ISSN: 0008-543X *
See also references of WO0077258A1 *
VELTRI ROBERT W ET AL: "Quantitative nuclear morphometry, Markovian texture descriptors, and DNA content captured on a CAS-200 image analysis systems, combined with PCNA and HER-2/neu immunohistochemistry for prediction of prostate cancer progression.", JOURNAL OF CELLULAR BIOCHEMISTRY SUPPLEMENT, no. 19, 1994, pages 249 - 258, XP002213574, ISSN: 0733-1959 *
YAMASAKI ICHIRO ET AL: "Overexpression of MDM2 and p53 protein is infrequently but significantly associated with progression of human prostatic adenocarcinoma.", ONCOLOGY REPORTS, vol. 3, no. 5, 1996, pages 925 - 929, XP002213570, ISSN: 1021-335X *
ZHAU H E ET AL: "Expression of c-erb B-2/neu proto-oncogene in human prostatic cancer tissues and cell lines.", MOLECULAR CARCINOGENESIS. UNITED STATES 1992, vol. 5, no. 4, 1992, pages 320 - 327, XP002213573, ISSN: 0899-1987 *

Also Published As

Publication number Publication date
EP1208232A1 (en) 2002-05-29
EP1512755A2 (en) 2005-03-09
EP1512755A3 (en) 2007-11-21
WO2000077258A1 (en) 2000-12-21
CA2375228A1 (en) 2000-12-21

Similar Documents

Publication Publication Date Title
AU2001253140A1 (en) Tumor markers in ovarian cancer
GB2349982B (en) Antenna
AU2001292802A1 (en) Genetic markers for tumors
HUP0303749A3 (en) Renal cell carcinoma tumor markers
AU2002212527A1 (en) Thermometry-based breast cancer risk assessment
EP0975803A4 (en) Method for assessing prostate cancer
EP1100886A4 (en) Tumor necrosis factor-gamma
IL145293A0 (en) Slide mounted antenna
AU2002360345A1 (en) Prostate cancer genes
GB9805877D0 (en) Cancer
EP1208232A4 (en) Markers for prostate cancer
GB9902685D0 (en) Antenna
GB2347792B (en) Antenna
EP1232176A4 (en) Tumour suppressor factor
AU2003280693A1 (en) Prostate cancer tumor marker
GB2383901B (en) An antenna
GB0006695D0 (en) Breast cancer markers
AU4598100A (en) Treating cancer
GB9708190D0 (en) Cancer marker
AU3350700A (en) Tumor marker zsig62
GB0031166D0 (en) Tumour Marker
AU4517799A (en) Combined cancer marker
GB0005466D0 (en) Cancer
GB9804050D0 (en) Cancer
AUPQ997300A0 (en) Prostate cancer diagnosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12Q 1/68 A, 7C 07H 21/04 B, 7G 01N 33/574 B

A4 Supplementary search report drawn up and despatched

Effective date: 20021129

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030407

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040929